Zentalis Pharmaceuticals, Inc. (ZNTL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Julie M. Eastland M.B.A. | CEO, President & Director | 397.08k | -- | 1964 |
| Ms. Andrea Paul J.D. | Chief Legal Officer & Corporate Secretary | 733k | -- | 1981 |
| Mr. Vincent A. Vultaggio | SVP of Finance & Principal Accounting Officer | -- | -- | 1984 |
| Ms. Wendy Chang | Chief People Officer | -- | -- | -- |
| Ms. Kimberly Freeman | Chief Strategy Officer | -- | -- | -- |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer | -- | -- | 1975 |
| Mr. Haibo Wang | Chief Business Officer | -- | -- | -- |
Zentalis Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 166
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 7, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Zentalis Pharmaceuticals, Inc. Earnings Date
Recent Events
April 2, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission